Ferguson Wellman Capital Management Inc. Purchases 718 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ferguson Wellman Capital Management Inc. boosted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 27,692 shares of the medical research company’s stock after acquiring an additional 718 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in Edwards Lifesciences were worth $2,050,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences during the 4th quarter worth about $30,000. FSA Wealth Management LLC bought a new position in Edwards Lifesciences during the 3rd quarter worth about $30,000. Prospera Private Wealth LLC bought a new position in Edwards Lifesciences during the 3rd quarter worth about $32,000. Avior Wealth Management LLC increased its holdings in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth about $46,000. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the subject of a number of recent research reports. The Goldman Sachs Group increased their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Piper Sandler reduced their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Finally, Robert W. Baird reduced their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $79.19.

Edwards Lifesciences Stock Up 1.0 %

Shares of EW opened at $71.05 on Tuesday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The firm’s 50 day moving average is $72.45 and its 200-day moving average is $69.18. The stock has a market capitalization of $41.91 billion, a PE ratio of 10.25, a P/E/G ratio of 3.64 and a beta of 1.10. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 8,000 shares of company stock valued at $547,430. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.